Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld Sells 76 Shares of Company Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 76 shares of the company’s stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $198.13, for a total transaction of $15,057.88. Following the sale, the executive vice president owned 19,568 shares in the company, valued at $3,877,007.84. The trade was a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Monday, September 28th, Michael Feld sold 76 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $183.70, for a total value of $13,961.20.
• On Wednesday, August 26th, Michael Feld sold 165 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock traded down $0.67 during mid-day trading on Tuesday, hitting $195.72. 618,536 shares of the stock were exchanged, compared to its average volume of 2,426,904. The stock’s fifty day simple moving average is $185.38 and its two-hundred day simple moving average is $170.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $200.47. The stock has a market capitalization of $53.93 billion, a price-to-earnings ratio of 58.94, a P/E/G ratio of 13.41 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the firm earned $3.68 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BDX. Generali Asset Management SPA SGR increased its stake in shares of Becton, Dickinson and Company by 6.2% during the third quarter. Generali Asset Management SPA SGR now owns 18,301 shares of the medical instruments supplier’s stock valued at $3,276,000 after acquiring an additional 1,068 shares during the period. Latitude Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the third quarter valued at approximately $58,000. Park Avenue Securities LLC boosted its position in shares of Becton, Dickinson and Company by 5.5% in the third quarter. Park Avenue Securities LLC now owns 3,115 shares of the medical instruments supplier’s stock worth $558,000 after buying an additional 161 shares during the period. Verdence Capital Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 65.2% in the 3rd quarter. Verdence Capital Advisors LLC now owns 2,670 shares of the medical instruments supplier’s stock valued at $478,000 after purchasing an additional 1,054 shares during the period. Finally, Deroy & Devereaux Private Investment Counsel Inc. lifted its position in Becton, Dickinson and Company by 0.8% in the 3rd quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 215,321 shares of the medical instruments supplier’s stock worth $38,542,000 after buying an additional 1,694 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on BDX shares. Bank of America increased their price target on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, August 31st. UBS Group started coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 price target for the company. Weiss Ratings raised shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 28th. Barclays started coverage on shares of Becton, Dickinson and Company in a research note on Wednesday, October 7th. They set an “underweight” rating and a $165.00 price objective on the stock. Finally, Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $185.07.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.